Tue Sep 17 05:49:45 UTC 2024: ## Fulcrum Therapeutics (FULC) Sees Upgraded Earnings Estimates, But Stock Faces Downgrades

**New York, NY** – Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company, has seen its FY2024 earnings per share (EPS) estimates upgraded by Leerink Partners, with analyst J. Schwartz forecasting a loss of ($0.32) per share, up from their previous prediction of ($0.43). However, the company’s stock has faced a wave of downgrades from various investment firms.

Leerink Partners currently holds a “Hold” rating on FULC, while the consensus estimate for the company’s full-year earnings sits at ($0.48) per share. Other analysts have issued varied projections for the company’s future earnings, including Q4 2024, Q1 2025, and even FY2026.

Despite the positive earnings adjustment, a number of other research firms have downgraded FULC’s stock. Cantor Fitzgerald, Bank of America, Stifel Nicolaus, HC Wainwright, and Royal Bank of Canada have all lowered their ratings and price targets for the company. The stock currently holds a consensus rating of “Hold” with an average target price of $9.33.

Fulcrum Therapeutics recently reported $0.87 EPS for the quarter ending July 31st, exceeding analysts’ estimates. The company’s focus is on developing products for treating genetically defined diseases. Their product candidates include losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy, and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia.

While the company’s recent earnings have been positive, the wave of downgrades suggests uncertainty surrounding its future performance. Investors will be watching closely to see how the company’s clinical trials progress and whether these developments can translate into sustained growth and profitability.

Read More